Company / Free Cash Flow
IOVANCE BIOTHERAPEUTICS, INC. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$336.2M
FY2025
5-year range
-$384.1M / -$265.5M
FY2021-FY2025
Trend
+7.6%
vs FY2024
Sector context
#174 of 194
Health Care
What the data says
Among 194 Health Care companies, IOVANCE BIOTHERAPEUTICS, INC. is in the bottom 10% for free cash flow. Improved from -$384M to -$336M over the past 2 years.
Based on SEC 10-K filings.
-$336M in FY2025.
Improved from -$384M to -$336M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 194This company -$336.2M Sector average $470.8M
▼
-171.4% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 7.6% year-over-year.
- Ranks #174 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$336.2M | +7.6% |
| FY2024 | -$364.0M | +5.2% |
| FY2023 | -$384.1M | -22.6% |
| FY2022 | -$313.2M | -18.0% |
| FY2021 | -$265.5M | -5.4% |
| FY2020 | -$251.9M | -51.9% |
| FY2019 | -$165.8M | -61.8% |
| FY2018 | -$102.4M | -28.5% |
| FY2017 | -$79.7M | -679.8% |
| FY2016 | -$10.2M | -178.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026